RA CAPITAL MANAGEMENT, L.P. recently filed their 13F report for the third quarter of 2022, which ended on 2022-09-30.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
200 BERKELEY STREET, 18TH FLOOR Boston, MA 02116
As of the latest 13F report, the guru’s equity portfolio contained 81 stocks valued at a total of $4.69Bil. The top holdings were ASND(16.67%), BIIB(5.34%), and CTKB(4.20%).
According to GuruFocus data, these were RA CAPITAL MANAGEMENT, L.P.’s top five trades of the quarter.
Vor Biopharma Inc
During the quarter, RA CAPITAL MANAGEMENT, L.P. bought 10,327 shares of NAS:VOR for a total holding of 11,131,300. The trade had a 0% impact on the equity portfolio. During the quarter, the stock traded for an average price of $3.98.
On 11/15/2022, Vor Biopharma Inc traded for a price of $4.3 per share and a market cap of $166.26Mil. The stock has returned -75.77% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Vor Biopharma Inc has a price-book ratio of 0.92 and a EV-to-Ebitda ratio of -0.62.
89bio Inc
During the quarter, RA CAPITAL MANAGEMENT, L.P. bought 1,593,733 shares of NAS:ETNB for a total holding of 9,376,402. The trade had a 0.29% impact on the equity portfolio. During the quarter, the stock traded for an average price of $8.7.
On 11/15/2022, 89bio Inc traded for a price of $9.82 per share and a market cap of $456.99Mil. The stock has returned -44.36% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, 89bio Inc has a price-book ratio of 2.49 and a EV-to-Ebitda ratio of -3.33.
DICE Therapeutics Inc
During the quarter, RA CAPITAL MANAGEMENT, L.P. bought 1,640,000 shares of NAS:DICE for a total holding of 6,848,911. The trade had a 1.24% impact on the equity portfolio. During the quarter, the stock traded for an average price of $35.88.
On 11/15/2022, DICE Therapeutics Inc traded for a price of $33.23 per share and a market cap of $1.58Bil. The stock has returned 12.99% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, DICE Therapeutics Inc has a price-book ratio of 4.57, a EV-to-Ebitda ratio of -18.58 and a price-sales ratio of 365.15.
Imara Inc
The guru established a new position worth 3,220,825 shares in NAS:IMRA, giving the stock a 0.32% weight in the equity portfolio. Shares traded for an average price of $3.79 during the quarter.
On 11/15/2022, Imara Inc traded for a price of $4.62 per share and a market cap of $121.45Mil. The stock has returned 29.41% over the past year.
GuruFocus gives the company a financial strength rating of 10 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Imara Inc has a price-book ratio of 2.12 and a EV-to-Ebitda ratio of -1.65.
Inhibrx Inc
The guru established a new position worth 3,185,831 shares in NAS:INBX, giving the stock a 2.53% weight in the equity portfolio. Shares traded for an average price of $30.5 during the quarter.
On 11/15/2022, Inhibrx Inc traded for a price of $32.8 per share and a market cap of $1.43Bil. The stock has returned -24.14% over the past year.
GuruFocus gives the company a financial strength rating of 3 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Inhibrx Inc has a EV-to-Ebitda ratio of -13.01 and a price-sales ratio of 271.08.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
